G. Yi et al., PROGNOSTIC-SIGNIFICANCE OF SPECTRAL TURBULENCE ANALYSIS OF THE SIGNAL-AVERAGED ELECTROCARDIOGRAM IN PATIENTS WITH IDIOPATHIC DILATED CARDIOMYOPATHY, The American journal of cardiology, 75(7), 1995, pp. 494-497
The aim of this study was to assess whether spectral turbulence analys
is (STA) of the signal-averaged electrocardiogram (SAECG) is of progno
stic use in patients with idiopathic dilated cardiomyopathy. SAECGs we
re recorded at presentation in 84 patients with idiopathic dilated car
diomyopathy and STA was performed using 183 Del Mar software. STA was
abnormal (greater than or equal to 3 of the 4 standard parameters beyo
nd the normal range) in 31 patients (37%). Patients were followed for
a mean duration of 24 +/- 18 months (range 1 to 59) during which time
24 (29%) developed progressive heart failure (14 underwent cardiac tra
nsplantation), 4 died suddenly or had aborted sudden death, and the ot
hers remained clinically stable. Progressive heart failure occurred mo
re often in patients who had an abnormal versus a normal STA result (1
5 [48%] vs 9 [17%]; p <0.002). Actuarial survival revealed a 1-year su
rvival of 90% in patients with a normal STA result and 63% in patients
with an abnormal STA result (9 <0.01). The predictive ability of STA
to identify patients with progressive heart failure was sensitivity 63
%, specificity 77%, positive predictive value 54%, and negative predic
tive value 83%. Univariate analysis identified peak oxygen consumption
as having the largest relative risk for the development of progressiv
e heart failure (9.55, 95% confidence interval [CI] 2.1 to 43.9). Left
ventricular end-diastolic dimension (relative risk 4.18, 95% CI 1.5 t
o 11.4) and STA (relative risk 3.81, 95% CI 1.7 to 8.8) were also sign
ificantly associated with the development of progressive heart failure
. Multivariate analysis showed that STA had a relative risk of 3.20 (9
5% CI 1.04 to 9.80). Abnormalities of the SAECG using STA are common i
n patients with idiopathic dilated cardiomyopathy and are a noninvasiv
e marker of patients at increased risk of developing progressive heart
failure.